This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Asia
19 - 21 October, 2026
The Westin Miyako Kyoto
BOOK NOW
Menu
BOOK NOW
keyboard_arrow_right

Main Conference Day 2 - JT (Japan Time, GMT+09:00)

keyboard_arrow_leftSearch & Filter
search
Main Conference Day 2 - JT (Japan Time, GMT+09:00)
search
Showing 1 of 1 Streams
08:30 - 09:00
Morning Registration
Showing 1 of 1 Streams
09:00 - 09:30
[Case Study] Engineering the Impossible: Breakthrough Strategies for the Oral Delivery of Complex Biologics
  • Jais Bjelke - Principal Scientist, Novo Nordisk
Showing 1 of 1 Streams
09:30 - 10:00
Rational ADC Design: Optimizing Molecular Distribution and the Therapeutic Window for Solid Tumors
10:00 - 10:30
Novel, next-generation ADCs for autoimmune and inflammatory diseases
  • Jerome Boyd-Kirkup - Co-Founder & CSO, Hummingbird Bioscience, Singapore
Morning Break
Showing 1 of 1 Streams
10:30 - 11:00
Morning Break & Networking
Showing 1 of 1 Streams
11:00 - 11:30
Beyond conventional ADCs: A modular antibody-mimetic drug conjugate platform for flexible cancer targeting
  • Masayuki Tsuchiya - President, CEO, Complecure, Inc.
11:30 - 12:00
Innovative Delivery Platforms: Overcoming Biological Barriers
Showing 1 of 1 Streams
12:00 - 12:30
Antibody and albumin designs engineered for tailored outcome
  • Jan Terje Andersen - Professor, Biomedical Innovation, University of Oslo and Oslo University Hospital
Lunch
Showing 1 of 1 Streams
12:30 - 13:30
Lunch & Networking
Showing 1 of 1 Streams
13:30 - 14:00
The Next Generation of T-Cell Engagers: Leveraging Costimulation to Drive Efficacy in Solid Tumors
  • Starlynn Clarke - Senior Director, Preclinical Biology, Rondo Therapeutics
14:00 - 14:30
Decoding Macrophage–Fibroblast Crosstalk to Enable Next-Generation Anti-fibrotic Therapies
  • Daniel Simão - Head of the Bayer Pharma Lab, iBET – Instituto de Biologia Experimental e Tecnológica
14:30 - 15:00
Designing for Manufacturability to Streamline the Transition from Discovery to Clinical Production
Afternoon Break
Showing 1 of 1 Streams
15:00 - 15:30
Afternoon Break & Networking
Showing 1 of 1 Streams
15:30 - 16:00
Navigating Path to Clinical Transition to Overcome Regulatory & CMC Hurdles
Showing 1 of 1 Streams
16:00 - 17:00
2026 Innovation Outlook: Balancing Speed, Safety, and Complexity in the Global Antibody Market
END OF CONFERENCE
Showing 1 of 1 Streams
17:00 - 17:05
END OF ANTIBODY ENGINEERING & THERAPEUTICS ASIA 2026
Main Conference Day 1
Filter
Streams
Choose Day